Ligand Pharmaceuticals (LGND) Profit After Tax (2016 - 2025)
Historic Profit After Tax for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $117.3 million.
- Ligand Pharmaceuticals' Profit After Tax rose 173515.06% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 737.56%. This contributed to the annual value of -$4.0 million for FY2024, which is 10749.18% down from last year.
- As of Q3 2025, Ligand Pharmaceuticals' Profit After Tax stood at $117.3 million, which was up 173515.06% from $4.8 million recorded in Q2 2025.
- Ligand Pharmaceuticals' Profit After Tax's 5-year high stood at $117.3 million during Q3 2025, with a 5-year trough of -$51.9 million in Q2 2024.
- Moreover, its 5-year median value for Profit After Tax was $4.8 million (2025), whereas its average is $10.2 million.
- As far as peak fluctuations go, Ligand Pharmaceuticals' Profit After Tax crashed by 236685.59% in 2024, and later soared by 173515.06% in 2025.
- Over the past 5 years, Ligand Pharmaceuticals' Profit After Tax (Quarter) stood at -$5.4 million in 2021, then tumbled by 222.78% to -$17.5 million in 2022, then soared by 204.02% to $18.2 million in 2023, then tumbled by 270.93% to -$31.1 million in 2024, then soared by 477.23% to $117.3 million in 2025.
- Its Profit After Tax stands at $117.3 million for Q3 2025, versus $4.8 million for Q2 2025 and -$42.5 million for Q1 2025.